COMPUMEDICS LIMITED — Regulatory Filings 2011

Dec 12, 2011

==> picture [76 x 78] intentionally omitted <==

ASX / MEDIA RELEASE

13[th] December 2011

Another Compumedics milestone EEG contract win – AUD 1 million at Yale University, USA

Melbourne, Australia, 13 December 2011 -- Compumedics Limited (ASX:CMP) today announced another significant milestone of being awarded the contract to supply EEG equipment for the Neurology Department at Yale School of Medicine, Yale University, USA. Under the contract Compumedics will supply its latest EEG products comprising the new Compumedics NEUVO® Long-Term EEG Monitoring (LTEM) system, Grael®HD, Profusion EEG 4 and Curry® NS7 software. The systems are to be used for routine clinical EEG and surgical monitoring. This purchase represents another major milestone in Compumedics’ strategic entry into the global $250 million p.a. LTEM/neurology market.

The sale, with an order value of more than AUD1 million, will see the installation of Compumedics’ latest EEG products into Yale University and follows several other significant EEG orders in the USA in the first half of FY2012. The NEUVO® LTEM systems can record a minimum 64 individual channels of high-density EEG data on a single patient for days or weeks at a time. The Grael®HD system provides high definition EEG signals while the Siesta®802 remains the industry’s most compact wireless EEG recording device. Compumedics' digital amplifier technology and breadth of EEG diagnostic offerings is state-of-the-art and provides Compumedics with a unique point of differentiation from competing offerings. Compumedics’ products provide higher quality brain recordings and more precise brain analysis than alternatives, helping to improve patient outcomes.

The Department of Neurology at Yale School of Medicine describes itself as a research, teaching, and clinical centre devoted to improving the understanding and treatment of diseases of the nervous system. The department is a major part of the Yale University School of Medicine and has several active clinical programs at local medical establishments.

Compumedics® equipment will help the Department of Neurology to achieve its goal of providing the highest level of patient care through state-of-the-art clinical programs, educating future leaders in the field of neurology and being at the forefront of

P a g e | 1

CMP ASX Release

13 December 2011

neuroscience research within one of the world’s most prestigious universities. The department has a long history of being a pioneer in the field of Neurology, such as establishing one of the first epilepsy monitoring units and creating one of the first stroke centres.

Dr. David Burton, Chairman and Chief Executive Officer of Compumedics Group commented,

"This contract is another important milestone for our Company. It reinforces our commitment to our customers and the patients under their care. Compumedics has made significant investments in product development, targeting the neuro-diagnostics market to leverage its expertise in high-end amplifier design and physiological signal processing. The world-class Yale University installation will establish a new and innovative standard for long-term EEG monitoring. This project further underpins our strategy to grow our business across this important, but relatively new, market sector for Compumedics. In particular, this prestigious sale to one of the world’s pre-eminent epilepsy monitoring centres validates our key growth strategy to penetrate the global LTEM market. The LTEM market alone is more than twice the size of our existing core sleep diagnostic business.”

About Compumedics

Compumedics Limited, was founded in 1987 by current Chairman/CEO Dr. David Burton and today is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific’s first fully computerized sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In 1995 the company was selected to supply equipment to the US Sleep Heart Health Study, the world’s largest sleep study of its kind, with over 8,000 participants scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe its products are distributed in over 50 countries. In 1998 Compumedics was awarded the overall Australian Exporter of the Year. In 2000 Compumedics was listed on the Australian Stock Exchange. In 2002 , Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In 2003 Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. I n 2004 , Compumedics acquired Germany-based DWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In 2006 , Compumedics was awarded the Frost and Sullivan Technology Leadership award for its innovative Somté® recorder product. In 2007 , Compumedics and its Chairman were inducted into the Victorian Manufacturing Hall of Fame. In 2008 the DWL division received a top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics Compumedics sales have grown more than 4-fold from $9 million (1999) to $39 million (2008). In 2009 Compumedics was awarded a design award for its GRAEL® PSG/EEG premium laboratory-based product. In 2010 Compumedics was recognized by the Australian Innovation Government and Industry body as one of Australia's Top 100 Health Innovators through its' world leading devices for sleep diagnostics. For further background please visit: www.compumedics.com http://www.compumedics.com

For further information please contact:

Compumedics Chairman/CEO: Dr. David Burton 61-3-8420-7300; dburton@compumedics.com.au

Bourse Communications: Mr. Rod North T: 03 9510 8309 M: 0408 670 706 E:rod@boursecommunications.com.au Investors: CMP.ASX (ASX.COM)

P a g e | 2

CMP ASX Release

13 December 2011